Osimertinib Versus Erlotinib or Gefitinib in The FLAURA Trial

Joshua Bauml, MD of the University of Pennsylvania discusses Osimertinib v Erlotinib or Gefitinib in the FLAURA Trial from the 22nd Annual Perspectives in Thoracic Oncology in New York <a target='_blank' href='http://imedex.c'>http://imedex.c...</a>... Author: thoraciconcology Added: 12/28/2017
Source: Oncology Tube - Category: Cancer & Oncology Source Type: podcasts